Mr. Francois Roberge reports

LSL PHARMA GROUP ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

LSL Pharma Group Inc. has released the voting results of its annual general and special meeting of shareholders held in a hybrid format on June 19, 2026.

Election of directors

All director nominees, namely Francois Roberge, Frank Dellafera, Mario Paradis, Louis Laflamme and Noureddine Mokaddem, were elected to hold office until the next annual meeting of shareholders or until their successors are appointed or elected.

Appointment of auditor

Audacie Inc. was reappointed as auditor of the corporation for the ensuing year, and the directors are authorized to fix its remuneration.

Reapproval of stock option plan

The current 10-per-cent rolling stock option plan of the corporation was reapproved until the next annual meeting of shareholders.

Grant of stock options

The corporation's disinterested shareholders approved, confirmed and ratified the prior grant of an aggregate 960,000 incentive stock options to certain directors, officers and employees of the corporation, approved by the board of directors on Feb. 3, 2026.

New equity incentive plan

The corporation's shareholders also approved the new equity incentive plan of the corporation.

The EIP is a fixed 10-per-cent security-based compensation plan, as defined in Policy 4.4 (Security Based Compensation) of the TSX Venture Exchange, pursuant to which the number of common shares in the capital of the company that are issuable upon the exercise of equity awards granted under the EIP shall not exceed 12,672,981 shares, representing 10 per cent of the issued and outstanding shares of the corporation as at April 24, 2026, the date at which the EIP was adopted.

Pursuant to the EIP, directors, officers, employees, management company employees and consultants of the corporation or its subsidiaries may be granted restricted share units, deferred share units and other share-based awards, as determined by the board of directors. The EIP is intended to provide the corporation with flexibility in designing various equity-based compensation arrangements to reward eligible participants for their contributions toward the long-term goals and success of the corporation and to enable and encourage such eligible participants to acquire shares as long-term investments and proprietary interests in the corporation. The EIP is administered by the board of directors, which has sole and complete authority, in its discretion, to determine the eligible participants to whom awards may be granted, the number of awards to be granted, and the terms and conditions of such awards, including the time of grant, vesting provisions, settlement terms, performance conditions, and any restrictions or limitations applicable thereto.

The EIP was conditionally approved by the TSX-V on May 8, 2026. It remains subject to the final acceptance of the TSX-V and must be reapproved by shareholders on an annual basis at the company's annual meeting of shareholders in accordance with the policies of the TSX-V.

For more information, please see the management information circular in respect of the meeting dated May 14, 2026, which includes a summary of the EIP and a copy thereof as Schedule B, available at the corporation's profile on SEDAR+.

The circular and full voting results are available on SEDAR+.

About LSL Pharma Group Inc.

LSL Pharma is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Leveraging its technical expertise, certified facilities and experienced management team, LSL Pharma delivers high-quality solutions that meet the most stringent industry standards. The wholly owned subsidiaries of LSL Pharma include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Sante Inc., Dermolab Pharma Ltd., Laboratoire Du-Var Inc. and Juno OTC Inc.

We seek Safe Harbor.